- Home
- RQI vs GUTS Comparison
RQI vs GUTS Comparison
Compare RQI & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RQI
- GUTS
- Stock Information
- Founded
- RQI 2002
- GUTS 2010
- Country
- RQI United States
- GUTS United States
- Employees
- RQI N/A
- GUTS N/A
- Industry
- RQI Trusts Except Educational Religious and Charitable
- GUTS
- Sector
- RQI Finance
- GUTS
- Exchange
- RQI Nasdaq
- GUTS NYSE
- Market Cap
- RQI 1.7B
- GUTS 58.8M
- IPO Year
- RQI N/A
- GUTS 2024
- Fundamental
- Price
- RQI $12.32
- GUTS $1.62
- Analyst Decision
- RQI
- GUTS Buy
- Analyst Count
- RQI 0
- GUTS 1
- Target Price
- RQI N/A
- GUTS $10.00
- AVG Volume (30 Days)
- RQI 432.6K
- GUTS 916.8K
- Earning Date
- RQI 01-01-0001
- GUTS 08-13-2025
- Dividend Yield
- RQI 8.20%
- GUTS N/A
- EPS Growth
- RQI N/A
- GUTS N/A
- EPS
- RQI N/A
- GUTS N/A
- Revenue
- RQI N/A
- GUTS $60,000.00
- Revenue This Year
- RQI N/A
- GUTS N/A
- Revenue Next Year
- RQI N/A
- GUTS N/A
- P/E Ratio
- RQI N/A
- GUTS N/A
- Revenue Growth
- RQI N/A
- GUTS N/A
- 52 Week Low
- RQI $9.17
- GUTS $0.87
- 52 Week High
- RQI $12.64
- GUTS $4.92
- Technical
- Relative Strength Index (RSI)
- RQI 49.60
- GUTS 46.09
- Support Level
- RQI $12.15
- GUTS $1.64
- Resistance Level
- RQI $12.65
- GUTS $1.82
- Average True Range (ATR)
- RQI 0.17
- GUTS 0.22
- MACD
- RQI -0.01
- GUTS -0.07
- Stochastic Oscillator
- RQI 38.00
- GUTS 12.22
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the Fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.